Deal Library / Pharma BD Deal Intelligence

Sanofi SA — Pharma Deals

The Pharma Closeout tracks 53 deals, $155.7B in disclosed deal value, 27 with a post-close Outcome Score for Sanofi SA.

Median Critic Score: 75  ·  Median Outcome Score: 61

Best outcome: Sanofi SA / Regeneron Pharmaceuticals, Inc. (97)  ·  Weakest outcome: Sanofi SA / Synthorx Inc. (15)

All 53 deals

• Sanofi SA / Regeneron Pharmaceuticals, Inc. — 2007 · $1.0B · Worked — the deal delivered on its rationale.
• Sanofi SA / Genzyme Corporation — 2011 · $20.1B · Worked — the deal delivered on its rationale.
• Sanofi SA / Synthelabo S.A. — 1998 · $11.0B · Worked — the deal delivered on its rationale.
• Sanofi SA / Amunix Pharmaceuticals Inc. — 2021 · $1.2B · Worked — the deal delivered on its rationale.
• Sanofi SA / Genzyme Corporation — 2010 · $18.5B · Worked — the deal delivered on its rationale.
• Sanofi SA / Translate Bio Inc. — 2018 · $805M · Largely worked — most objectives met.
• Sanofi SA / Protein Sciences Corp. — 2017 · $650M · Largely worked — most objectives met.
• Sanofi SA / Inhibrx Inc. — 2024 · $2.2B · Largely worked — most objectives met.
• Sanofi SA / Provention Bio Inc. — 2023 · $2.9B · Largely worked — most objectives met.
• Sanofi SA / Dynavax Technologies — 2025 · $2.2B · Largely worked — most objectives met.
• Sanofi SA / Ablynx NV — 2018 · $4.8B · Largely worked — most objectives met.
• Sanofi SA / Sino Biopharmaceutical Ltd. — 2026 · $1.5B · Largely worked — most objectives met.
• Sanofi SA / Chattem Inc. — 2009 · $1.9B · Largely worked — most objectives met.
• Sanofi SA / Kadmon Holdings Inc. — 2021 · $1.9B · Largely worked — most objectives met.
• Sanofi SA / Regeneron Pharmaceuticals, Inc. — 2015 · $2.2B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Bioverativ Inc. — 2018 · $11.6B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Kymab Ltd — 2021 · $1.4B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Novavax Inc. — 2024 · $1.2B · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Rhône-Poulenc — 1895 · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Lexicon Pharmaceuticals Inc. — 2015 · $1.7B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Kiadis Pharma NV — 2020 · $359M · Underwhelmed — fell short of the thesis.
• Sanofi SA / Principia Biopharma — 2020 · $3.7B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Ablynx NV — 2017 · $2.7B · Underwhelmed — fell short of the thesis.
• Sanofi SA / Alnylam Pharmaceuticals, Inc. — 2014 · $700M · Underwhelmed — fell short of the thesis.
• Sanofi SA / Translate Bio Inc. — 2021 · $3.2B · Underwhelmed — fell short of the thesis.
• Sanofi SA / TargeGen, Inc. — 2010 · $560M · Underwhelmed — fell short of the thesis.
• Sanofi SA / Synthorx Inc. — 2019 · $2.5B · Did not work — the deal failed to deliver.
• Sanofi SA / Kali Therapeutics, Inc. — 2026 · $1.2B
• Sanofi SA / Chia Tai Tianqing Pharmaceutical Group (subsidiary of Sino Biopharmaceutical Limited) — 2026 · $1.5B
• Sanofi SA / Vigil Neuroscience, Inc. — 2025 · $600M
• Sanofi SA / Dren Bio, Inc. — 2025 · $1.8B
• Sanofi SA / Dren Bio, Inc. — 2025 · $1.9B
• Sanofi SA / Blueprint Medicines Corporation — 2025 · $9.5B
• Sanofi SA / ADEL, Inc. — 2025 · $1.0B
• Sanofi SA / Earendil Labs, Inc. — 2025 · $1.8B
• Sanofi SA / BioMap Holdings Limited — 2023 · $1.0B
• Sanofi SA / Maze Therapeutics, Inc. — 2023 · $750M
• Sanofi SA / Teva Pharmaceutical Industries Ltd. — 2023 · $1.5B
• Sanofi SA / Janssen Pharmaceuticals, Inc. (Johnson & Johnson) — 2023 · $175M
• Sanofi SA / Exscientia plc — 2022 · $5.3B
• Sanofi SA / Innate Pharma SA — 2022 · $1.4B
• Sanofi SA / IGM Biosciences Inc. — 2022 · $6.2B
• Sanofi SA / Adagene Inc. — 2022 · $2.5B
• Sanofi SA / Atomwise Inc. — 2022 · $1.0B
• Sanofi SA / Skyhawk Therapeutics Inc. — 2022 · $2.1B
• Sanofi SA / Insilico Medicine Inc. — 2022 · $1.2B
• Sanofi SA / Origimm Biotechnology GmbH — 2021 · $170M
• Sanofi SA / Tidal Therapeutics, Inc. — 2021 · $470M
• Sanofi SA / Owkin, Inc. — 2021 · $270M
• Sanofi SA / Kymera Therapeutics, Inc. — 2020 · $2.1B
• Sanofi SA / Translate Bio Inc. — 2020 · $2.3B
• Sanofi SA / Hanmi Pharmaceutical Co., Ltd. (Quantum Project) — 2015 · $4.2B
• Sanofi SA / MannKind Corporation — 2014 · $925M

← Deal Library  ·  Interactive search  ·  How we score deals